Why Leen Kawas Believes Venture Capital Must Be Mission-Driven
For Leen Kawas, investing in biotechnology is not simply a financial act — it’s an ethical one. As co-founder and managing general partner of Propel Bio Partners, and CEO of EIT Pharma, Kawas approaches venture capital through a distinctly human lens. Her belief is clear: the future of healthcare depends on investors who see beyond returns and focus on purpose. For her, mission-driven capital is not philanthropy — it’s precision investment aligned with impact.
Kawas’s perspective comes from experience across every level of biotech, from the lab bench to the boardroom. A scientist and inventor by training, she first made her mark as the co-founder and CEO of Athira Pharma, leading the company through groundbreaking neurological research and into a successful IPO in 2020. That journey — raising over $400 million and becoming one of only 22 women founders in the U.S. to take a company public — taught her how fragile and powerful the bridge between innovation and investment can be. In her view, mission-driven capital strengthens that bridge, ensuring that scientific potential translates into patient outcomes.
She often describes venture capital as the bloodstream of innovation — a flow of resources that determines which ideas live or die. Traditional investing, she argues, too often favors speed and scale over substance. When applied to biotechnology, that mindset can distort priorities, pushing companies to pursue quick wins rather than meaningful breakthroughs. Mission-driven capital, by contrast, starts with a clear north star: improving human health. It seeks partners who share that vision and measures success not only by returns but by reach — how far the science travels, and how many lives it can touch.
Propel Bio Partners, the fund Kawas co-founded, was built on this principle. Its portfolio supports life science startups developing transformative therapies and technologies. Yet the firm’s mission extends beyond funding. It provides operational guidance, strategic partnerships, and mentorship designed to help founders build resilient, ethically grounded companies. Kawas emphasizes that investing in biotech is as much about cultivating character as it is about capitalizing on innovation. The most effective founders, she notes, combine technical excellence with empathy — a rare but necessary mix when the stakes involve human life.
Her approach reflects a broader conviction that the business of medicine must be human-centered to remain sustainable. Mission-driven investment, she explains, aligns incentives between science, patient care, and shareholder value. It challenges the false dichotomy between profit and purpose. When done right, it creates a feedback loop where doing good and doing well become mutually reinforcing. Breakthroughs attract capital; capital accelerates breakthroughs. Everyone benefits — especially the people waiting for solutions.
Leen Kawas’s own leadership style embodies this integration of rigor and empathy. She views innovation as a moral responsibility: the privilege of working on discoveries that could heal. As a scientist, she understands the weight of that responsibility. As an investor, she understands how to protect and propel it. Her experience navigating clinical trials, regulatory landscapes, and public markets has given her a rare vantage point — one that informs her belief that mission-driven capital is not just idealism but sound strategy.
She often points to diversity as a key part of that mission. In her view, a truly impactful biotech ecosystem must reflect the diversity of the patients it serves. This means broadening representation among founders, executives, and investors alike. Through her role on the board of Inherent Biosciences and her mentorship initiatives, Kawas advocates for inclusivity as a source of innovation. Different perspectives, she argues, yield better science and better companies. Mission-driven investing therefore requires not just funding ideas, but funding who gets to create them.
Kawas’s vision of venture capital challenges the industry’s traditional metrics of success. She asks investors to consider longevity — not just exit strategies. A mission-driven fund looks at what kind of legacy it will leave in the scientific landscape: the technologies it enabled, the companies it strengthened, the treatments it made possible. In a field where timelines stretch across decades, patience and purpose become strategic advantages.
Her work with Propel Bio Partners represents a model for what this new kind of venture leadership can look like. The firm’s philosophy is guided by stewardship rather than speculation, and by the belief that long-term value stems from long-term vision. Kawas frequently reminds her peers that healthcare innovation is not an abstract asset class — it’s a human continuum. Every investment has downstream consequences for patients, families, and communities. To ignore that is to misunderstand the nature of the work itself.
Leen Kawas’s insistence that venture capital must be mission-driven comes from the intersection of science and conscience. She has seen how transformative breakthroughs begin not only with discovery but with belief — the belief that health equity, innovation, and business success can coexist. Her leadership offers a blueprint for a new era of biotech investment: one defined not by speculation, but by stewardship; not by hype, but by healing.
In her words and her work, Kawas continues to prove that capital, when aligned with purpose, becomes more than money — it becomes momentum for human progress.
Learn more about Leen Kawas and her business philosophy in this interview at the link below: